A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Read more about A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident. Read more about Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident.
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Read more about Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Read more about Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Read more about Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.
Guidelines for the welfare and use of animals in cancer research. Read more about Guidelines for the welfare and use of animals in cancer research.
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Read more about Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Read more about Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Read more about Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Read more about Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.
